Literature DB >> 2221370

Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma.

R L Thies1, D W Cowens, P R Cullis, M B Bally, L D Mayer.   

Abstract

To understand and predict the efficacy and/or toxicity of liposomal drugs in vivo, it is essential to have rapid, reliable methods of separating and quantitating both the free and the liposomal forms of the drug. A method using solid-phase extraction chromatography columns was developed to separate and quantitate unencapsulated doxorubicin and liposome-associated doxorubicin in plasma following the intravenous injection of liposomal doxorubicin. The method facilitated the recovery and quantitation of free and liposomal drug. The separation and recovery of doxorubicin were linear across the entire range of possible mixtures (0 to 100%) of the two forms of the drug in plasma. Free drug and liposomal drug were readily separated for liposomal doxorubicin systems varying in size (0.1-1.0 microns) and lipid composition (egg yolk phosphatidylcholine/cholesterol and distearylphosphatidylcholine/cholesterol). The method is rapid and allows for multiple samples to be processed simultaneously.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221370     DOI: 10.1016/0003-2697(90)90528-h

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

Review 2.  Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Authors:  R M Fielding
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 3.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.

Authors:  Min Li; Peng Zou; Katherine Tyner; Sau Lee
Journal:  AAPS J       Date:  2016-11-10       Impact factor: 4.009

4.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

Authors:  K M Wasan; M Ramaswamy; S M Cassidy; M Kazemi; F W Strobel; R L Thies
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Fabrication and development of pectin microsphere of metformin hydrochloride.

Authors:  Pritam Banerjee; Jyotirmoy Deb; Amitava Roy; Amitava Ghosh; Prithviraj Chakraborty
Journal:  ISRN Pharm       Date:  2012-08-01

6.  Stable isotope method to measure drug release from nanomedicines.

Authors:  Sarah Skoczen; Scott E McNeil; Stephan T Stern
Journal:  J Control Release       Date:  2015-10-24       Impact factor: 9.776

7.  Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.

Authors:  B A Conley; M J Egorin; M Y Whitacre; D C Carter; E G Zuhowski; D A Van Echo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.

Authors:  I F Uchegbu; J A Double; J A Turton; A T Florence
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

9.  Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.

Authors:  Wenqian Yang; Zimeng Yang; Jieru Liu; Dan Liu; Yongjun Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-11       Impact factor: 6.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.